Cyclo Therapeutics Cash Per Share vs. Beta

CYTHW Stock  USD 0.14  0.00  0.00%   
Based on Cyclo Therapeutics' profitability indicators, Cyclo Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Cyclo Therapeutics' ability to earn profits and add value for shareholders.
 
Cash Per Share  
First Reported
2010-12-31
Previous Quarter
0.56624339
Current Value
0.54
Quarterly Volatility
2.15209828
 
Credit Downgrade
 
Yuan Drop
 
Covid
At this time, Cyclo Therapeutics' Price To Sales Ratio is fairly stable compared to the past year. EV To Sales is likely to climb to 17.32 in 2024, despite the fact that Operating Cash Flow Sales Ratio is likely to grow to (14.28). At this time, Cyclo Therapeutics' Income Quality is fairly stable compared to the past year. Net Income Per E B T is likely to climb to 1.51 in 2024, despite the fact that Operating Income is likely to grow to (19 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.680.9085
Way Down
Slightly volatile
For Cyclo Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cyclo Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cyclo Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cyclo Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cyclo Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
For more information on how to buy Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclo Therapeutics. If investors know Cyclo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share
0.046
Quarterly Revenue Growth
0.051
Return On Assets
(2.82)
Return On Equity
(226.64)
The market value of Cyclo Therapeutics is measured differently than its book value, which is the value of Cyclo that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclo Therapeutics' market value can be influenced by many factors that don't directly affect Cyclo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Cyclo Therapeutics Beta vs. Cash Per Share Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Cyclo Therapeutics's current stock value. Our valuation model uses many indicators to compare Cyclo Therapeutics value to that of its competitors to determine the firm's financial worth.
Cyclo Therapeutics is rated fifth in cash per share category among its peers. It is rated below average in beta category among its peers . At this time, Cyclo Therapeutics' Cash Per Share is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Cyclo Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Cyclo Beta vs. Cash Per Share

Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

Cyclo Therapeutics

Cash Per Share

 = 

Total Cash

Average Shares

 = 
1.32 X
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.

Cyclo Therapeutics

Beta

 = 

Covariance

Variance

 = 
-0.38
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.

Cyclo Beta Comparison

Cyclo Therapeutics is currently under evaluation in beta category among its peers.

Beta Analysis

As returns on the market increase, returns on owning Cyclo Therapeutics are expected to decrease at a much lower rate. During the bear market, Cyclo Therapeutics is likely to outperform the market.

Cyclo Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Cyclo Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Cyclo Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Cyclo Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Cyclo Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Operating Income-20.1 M-19 M
Income Before Tax-20.1 M-19.1 M
Total Other Income Expense Net-7.2 K-7.6 K
Net Loss-20.1 M-19.1 M
Income Tax Expense 4.00  3.80 
Interest Income22.8 K15.8 K
Net Loss-13.9 M-13.2 M
Net Loss-19.4 M-18.4 M
Non Operating Income Net Other153.9 K136.8 K
Change To Netincome303 K269.3 K
Net Loss(1.23)(1.29)
Income Quality 0.81  0.85 
Net Income Per E B T 1.14  1.51 

Cyclo Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Cyclo Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Cyclo Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Cyclo Therapeutics' important profitability drivers and their relationship over time.

Use Cyclo Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cyclo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclo Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Cyclo Therapeutics Pair Trading

Cyclo Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Cyclo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cyclo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cyclo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cyclo Therapeutics to buy it.
The correlation of Cyclo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cyclo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cyclo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cyclo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Cyclo Therapeutics position

In addition to having Cyclo Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Energy Funds Thematic Idea Now

Energy Funds
Energy Funds Theme
Funds or Etfs investing in energy sector, natural resources, and ecology. The Energy Funds theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Energy Funds Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Cyclo Stock Analysis

When running Cyclo Therapeutics' price analysis, check to measure Cyclo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclo Therapeutics is operating at the current time. Most of Cyclo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclo Therapeutics' price. Additionally, you may evaluate how the addition of Cyclo Therapeutics to your portfolios can decrease your overall portfolio volatility.